Scott Simon Tykodi

Scott Tykodi practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Scott Tykodi's NPI, 1114002938, was assigned on October 27, 2006. Scott Tykodi graduated from Washington University School of Medicine in 1997. Scott Tykodi holds Washington license MD00038553.

Scott Tykodi's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Scott Tykodi's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Scott Tykodi is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Scott Tykodi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Scott Tykodi practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Scott Tykodi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Scott Tykodi is licensed in Washington.

CMS data shows 273 Medicare services from Scott Tykodi across 5 procedure codes in 2024, for 114 Medicare patients. Medicare paid $18,436 for them. Every service was in an office.

CMS counts 114 Medicare patients who saw Scott Tykodi in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Scott Tykodi's median patient age at 69, with 38% women.

In 2024, Scott Tykodi wrote 247 Medicare Part D claims for 45 patients. 49% of them were for generic drugs. CMS names the drug for 151 of them, across 6 drugs with 11 or more claims each, at $2,288,346 in total drug cost. In 2023, CMS named 154 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Scott Tykodi for performance year 2024, reported through an alternative payment model (APM). Scott Tykodi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Scott Tykodi as offering telehealth.

Dmand AI links 59 papers to Scott Tykodi, published from 2011 to 2025. 2022 was the busiest year, with 7. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Nivolumab. Scott Tykodi has published most often in J Immunother Cancer. Scott Tykodi's most frequent co-authors are David Francis McDermott, MD, Robert J. Motzer, MD and Toni K. Choueiri, MD.

Dmand AI links Scott Tykodi to 3 clinical trials. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and Clear-cell metastatic renal cell carcinoma.

CMS Open Payments shows 28 general payments to Scott Tykodi from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Merck Sharp & Dohme Corporation paid the most, $14,941.

Scott Tykodi graduated from Washington University School of Medicine in 1997.